NCT02635061View on ClinicalTrials.gov

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 25, 2016

Primary Completion Date

January 22, 2024

Study Completion Date

January 22, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

ACY-241

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

Trial Locations (1)

02215

Local Institution - 350, Boston

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY